Hoth Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Hoth Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Hoth Therapeutics Announces Engagement With Icon And Expansion Of Phase Ii Clinical Trial For Ht-001 In Europe
Brief: Hoth Therapeutics Signs VA Research Deal To Advance GDNF As Breakthrough Therapy For Obesity And Fatty Liver
Brief: Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics
Brief: Hoth Therapeutics Says 100% Of Patients Achieved Primary Endpoint In HT-001 Phase 2A Trial
Brief: Hoth Therapeutics Secures Japanese Patent For Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Brief: Hoth Therapeutics Launches Expanded Access Initiative For HT-001
Hoth Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Hoth Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial
Hoth Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development
Brief: Hoth Therapeutics Receives Uspto Filing Receipt For Ht-001 Formulation Patent Application, Expanding Existing Patent Coverage
Hoth Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
Hoth Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need
Brief: Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease